Edwards Lifesciences (NYSE:EW) is a leading medical technology company that specializes in artificial heart valves and systems used for monitoring blood flow. The company focuses on creating therapies for patients with serious structural heart disease, which are often used in complex cardiac procedures.
On July 23, 2026, Edwards Lifesciences reported strong second-quarter results. The company announced an adjusted earnings per share (EPS) of $0.78, beating the consensus estimate of $0.74. EPS is a measure of a company's profit allocated to each outstanding share of common stock, serving as an indicator of profitability.
The company's revenue also surpassed expectations, reaching $1.74 billion against an estimated $1.70 billion. This 13.6% increase in total sales was driven by strong demand for its heart devices. Sales from its Transcatheter Aortic Valve Replacement (TAVR) products grew 11.3% to $1.26 billion.
Following the positive news, Edwards Lifesciences' shares climbed nearly 7% in extended trading, as highlighted by Reuters. In response to its performance, Edwards Lifesciences adjusted its full-year sales outlook. It now projects sales to be between $6.6 billion and $6.9 billion for the year.
Edwards Lifesciences maintains a strong financial position with a low Debt-to-Equity ratio of 0.07, showing it relies less on debt. It also has a current ratio of 4.42. This suggests the company has more than four times the short-term assets needed to cover its short-term debts, indicating a solid ability to meet obligations.
